After several years spent honing its robotic cell therapy manufacturing system, Multiply Labs has snared its first collaboration with a major cell therapy developer. Multiply Labs and Legend ...

This partnership underscores the versatility of Multiply Labs’ robotic systems, showcasing their wide range of cell therapy applications, which include but are not limited to CAR-T therapy ...

Robotics specialist Multiply Labs and Thermo Fisher Scientific inked a deal to expand their partnership to further automate the cell therapy production process. The two companies will integrate ...

Multiply Labs, a robotics firm ... from different vendors which are already extensively deployed for cell and gene therapy manufacturing, pointed out Parietti, adding that this technology is ...

Multiply Labs collaborated with these life science industry leaders to demonstrate automated cell therapy manufacturing tasks, with an emphasis on cell expansion. The results of the proof-of ...

The company will combine Multiply Labs’ robotic automation with its cell engineering capabilities. “Cell therapy manufacturing infrastructure and its associated costs have severely limited the ...

By utilizing Multiply Labs' cell therapy robotic cluster and GenScript's GMP-grade CytoSinct 1000 cell isolation solution, capable of isolating up to 120X10^9 total cells within a single hour ...

Legend Biotech appears to be on a mission to shake up its cell therapy ... up to automate cell therapy production through the power of robotics via a collaboration with Multiply Labs.

IT’S EXPANDING ITS FACILITY IN ROCKVILLE SPECIFICALLY TO WORK ON CELL THERAPY IN SPECIALLY DESIGNED LABS. IT WILL ALLOW ASTRAZENECA TO EXPAND THE AVAILABILITY OF THE PROCEDURE ALL OVER THE WORLD.

It’s hoped the corrected blood stem cells will then multiply and create a new blood system, one free of sickle cell. Mark Walters, MD, is the principal investigator of the clinical trial and gene ...

It's hoped the corrected blood stem cells will then multiply and create a new blood system, one free of sickle cell. This therapy is intended to eliminate sickle cell disease by applying CRISPR ...